Patent: 10,261,083
✉ Email this page to a colleague
Summary for Patent: 10,261,083
Title: | Compositions and methods for detecting protease activity in biological systems |
Abstract: | The invention relates generally to compositions and methods for detecting protease activity in a subject or a biological sample using activatable antibodies, and the use of these compositions and methods in a variety of diagnostic indications. |
Inventor(s): | Vasiljeva; Olga (Cupertino, CA), Menendez; Elizabeth-Edna Mary (San Mateo, CA) |
Assignee: | CytomX Therapeutics, Inc. (South San Francisco, CA) |
Application Number: | 14/147,324 |
Patent Claims: | see list of patent claims |
Details for Patent 10,261,083
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | 05/05/2004 | ⤷ Try a Trial | 2033-01-04 |
Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | 12/02/2004 | ⤷ Try a Trial | 2033-01-04 |
Amphastar Pharmaceuticals, Inc. | AMPHADASE | hyaluronidase | Injection | 021665 | 10/26/2004 | ⤷ Try a Trial | 2033-01-04 |
Akorn, Inc. | HYDASE | hyaluronidase | Injection | 021716 | 10/25/2005 | ⤷ Try a Trial | 2033-01-04 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2033-01-04 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 05/12/1998 | ⤷ Try a Trial | 2033-01-04 |
Novartis Pharmaceuticals Corporation | SIMULECT | basiliximab | For Injection | 103764 | 01/02/2003 | ⤷ Try a Trial | 2033-01-04 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |